Day One Reports Second Quarter 2025 Financial Results and Corporate Progress

Core Insights - Day One Biopharmaceuticals reported a net product revenue of $33.6 million for OJEMDA in Q2 2025, marking a 10% increase from Q1 2025 and a 310% increase from Q2 2024 [1][5][12] - The company expects full-year 2025 net product revenue to be between $140 million and $150 million [1][5] - Day One ended Q2 2025 with $453.1 million in cash, cash equivalents, and short-term investments [1][12] OJEMDA Commercial Performance - OJEMDA prescriptions exceeded 1,000 in Q2 2025, representing a 15% increase from Q1 2025 and a 346% increase from Q2 2024 [5] - The total net product revenue for OJEMDA for the 12-month period ending June 30, 2025, was $113.1 million [5] Financial Highlights - Research and development expenses for Q2 2025 were $36.1 million, down from $92.1 million in Q2 2024, primarily due to a one-time upfront payment in the previous year [12] - Selling, general, and administrative expenses decreased to $29.0 million in Q2 2025 from $30.2 million in Q2 2024 [12] - The net loss for Q2 2025 was $30.3 million, compared to a net loss of $4.4 million in Q2 2024 [12] Corporate Developments - Michael Vasconcelles, M.D., joined Day One as Head of Research and Development in June 2025, bringing over 25 years of oncology research experience [6] - The company terminated its research collaboration and license agreement with Sprint Bioscience AB to align with its strategic objectives [5] Clinical Trials and Pipeline - DAY301, a PTK7-targeted ADC, is currently enrolling patients in the Phase 1a portion of its clinical trial [5] - Day One plans to present 3-year follow-up data from the FIREFLY-1 clinical trial in Q4 2025 [5] - Patient enrollment for the pivotal Phase 3 FIREFLY-2 clinical trial is on track for completion in the first half of 2026 [5]